Q3 2017 Argos Therapeutics Inc Earnings Call
Llamada en conferencia Argos Therapeutics Inc
Argos Therapeutics Inc Conference call or earnings call will be held on 13-nov-2017 via an 800 number (toll-free). During the earnings conference call's session Argos Therapeutics Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Argos Therapeutics Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are an immuno-oncology company focused on the development and commercialization of truly individualized immunotherapies for the treatment of cancer and infectious diseases based on our proprietary technology platform called Arcelis. Our most advanced product candidate is AGS-003, which we are developing for the treatment of metastatic renal cell carcinoma, or mRCC, and other cancers. We are currently conducting a pivotal Phase 3 clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment, or SPA, with the Food and Drug Administration, or FDA. We refer to this trial as the ADAPT trial. We initiated the ADAPT trial in January 2013, dosed the first patient in May 2013 and completed enrollment of the trial in July 2015.Leer más Llamada en conferencia